gefitinib   Click here for help

GtoPdb Ligand ID: 4941

Synonyms: Iressa® | ZD 1839 | ZD1839
Approved drug PDB Ligand
gefitinib is an approved drug (FDA (2003), EMA (2009))
Compound class: Synthetic organic
Comment: Gefitinib is an orally active Type-1 kinase inhibitor and was first approved by the US FDA in 2003. Gefitinib has selectivity for the EGFR [5].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: gefitinib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 68.74
Molecular weight 446.15
XLogP 3.18
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc2ncnc(c2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F
Isomeric SMILES COc1cc2ncnc(c2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F
InChI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI Key XGALLCVXEZPNRQ-UHFFFAOYSA-N
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
epidermal growth factor receptor Primary target of this compound Hs Inhibitor Inhibition 9.0 – 9.0 pKd - 2-3
pKd 9.0 (Kd 1x10-9 M) [3]
pKd 9.0 (Kd 1.1x10-9 M) [2]
epidermal growth factor receptor Primary target of this compound Hs Inhibitor Inhibition 8.3 pKi - 6
pKi 8.3 (Ki 5.5x10-9 M) [6]
Ligand mentioned in the following text fields